熱門資訊> 正文
Rani Therapeutics首席财务官桑福德将离职
2026-05-16 05:00
- Rani Therapeutics (RANI) said on Friday that chief financial officer Svai Sanford will leave the company after a successor is appointed, as the company announced a series of leadership changes and operational updates.
- Sanford, who helped lead Rani through its initial public offering and financing initiatives, will remain during a transition period to support an orderly handover, the company said.
- Rani said in its first quarter, co promoted Alireza Javadi to chief technical officer, appointed Jesper Høiland as head of strategy and named Sara Kenkare-Mitra as a strategic advisor.
- Stock down -2% in aftermarket trading after Rani posted Q1 GAAP EPS of -$0.04 in-line. Contract revenue of $1.7M (+900.0% Y/Y) beats by $1.2M.
More on Rani Therapeutics
- Rani Therapeutics Holdings, Inc. (RANI) Q4 2025 Earnings Call Transcript
- Rani Therapeutics GAAP EPS of -$0.04 in-line, revenue of $1.7M beats by $1.2M
- Seeking Alpha’s Quant Rating on Rani Therapeutics
- Historical earnings data for Rani Therapeutics
- Financial information for Rani Therapeutics
推薦文章
壓力測試過關 摩根大通、高盛等美國大型銀行提高股利並回購股份
華盛早報 | 美光盤后飆升近16%！炸裂財報引爆芯片股，納指期貨應聲漲2%；黃仁勛豪言AI進入盈利時代；高通全面進軍AI數據中心
港股概念追蹤 | 曝蘋果摺疊屏iPhone敲定7月底量產 產業鏈有望迎來高速發展拐點(附概念股)
美股前瞻 | AI風向標來襲！英偉達股東大會凌晨開始、美光財報盤后發佈；布油跌破75美元創戰后新低；海力士或7月10日登陸美股
谷歌一夜蒸發15000億，只因失去了兩個人
SpaceX通過債市募資250億美元 認購需求顯示市場心態謹慎
拋售SpaceX，買入特斯拉？
資金覆盤 | 北水逆勢抄底港股近104億港元！加倉中芯國際、建滔集團，拋售阿里巴巴
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
